SANN — Santhera Pharmaceuticals Holding AG Share News
0.000.00%
Last trade - 00:00- CH₣220.90m
- CH₣220.41m
- CH₣77.19m
Brief: Santhera Receives Positive CHMP Opinion Recommending Approval Of Agamree® (Vamorolone) For The Treatment Of Duchenne Muscular Dystrophy
Brief: Santhera Pharmaceuticals: Completes Divestment Of Raxone/Idebenone Business To Chiesi Farmaceutici S.P.A.
Brief: Santhera: Exclusive North America License Agreement With Catalyst For Vamorolone
Brief: Santhera Says Grants Exclusive North America License For Vamorolone To Catalyst Pharmaceuticals In Deal Valued At Up To USD 231 Mln Plus Royalties
Brief: Santhera Pharmaceuticals Holding AG Proposes A Reverse Share Split In Ratio 10:1
Brief: Santhera: 2022 Revenue From Contracts With Customers Of CHF 7.5 Mln
Swiss stocks - Factors to watch on March 2
Brief: Santhera Secures Additional Funding Through A Private Placement Of Shares
Brief: Santhera: Enters Into CHF 5 Mln Share Exchange Agreement
Brief: Santhera Says Submits Marketing Authorization Application To European Medicines Agency For Vamorolone In Duchenne Muscular Dystrophy
Swiss stocks - Factors to watch on September 29
Brief: Santhera: Finalization Of NDA Submission For Vamorolone Postponed
Swiss stocks - Factors to watch on June 29
Swiss stocks - Factors to watch on June 28
Brief: Santhera Nominates Thomas Meier To Succeed Elmar Schnee As Chairman Of The Board
Swiss stocks - Factors to watch on June 10
Brief: Santhera Pharmaceuticals FY Net Loss At CHF -55.5 Mln
Brief: Santhera And ReveraGen To Present New Data With Vamorolone
Swiss stocks - Factors to watch on April 13